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To assess the genetic consequences of induced
pluripotent stem cell (iPSC) reprogramming, we
sequenced the genomes of ten murine iPSC clones
derived from three independent reprogramming ex-
periments, and compared them to their parental
cell genomes.We detected hundreds of single nucle-
otide variants (SNVs) in every clone, with an average
of 11 in coding regions. In two experiments, all SNVs
were unique for each clone and did not cluster in
pathways, but in the third, all four iPSC clones con-
tained 157 shared genetic variants, which could
also be detected in rare cells (<1 in 500) within the
parental MEF pool. These data suggest that most
of the genetic variation in iPSC clones is not caused
by reprogramming per se, but is rather a conse-
quence of cloning individual cells, which ‘‘captures’’
their mutational history. These findings have implica-
tions for the development and therapeutic use of
cells that are reprogrammed by any method.
INTRODUCTION
The discovery of methods to create induced pluripotent stem
cells (iPSCs) in 2006 revolutionized the field of regenerative
medicine. Yamanaka et al. and Thomson et al. showed that
expression of a small set of transcription factors in mouse or
human somatic cells can reprogram a small subset to a pluripo-
tent state (Takahashi et al., 2007; Takahashi and Yamanaka,
2006; Yu et al., 2007). Subsequent modifications to the original
reprogramming protocols have decreased safety concerns and
increased efficiency. Reprogramming is now possible without
the use of c-myc (Chang et al., 2009; Huangfu et al., 2008b;
Wernig et al., 2008). It can be performed with single polycistronic570 Cell Stem Cell 10, 570–582, May 4, 2012 ª2012 Elsevier Inc.lentiviruses to limit integration-site-dependent mutagenesis
(Carey et al., 2009; Chang et al., 2009; Shao et al., 2009), or by
transiently expressing specific cDNAs, RNA molecules, or the
reprogramming proteins themselves in somatic cells (Okita
et al., 2008; Stadtfeld et al., 2008; Warren et al., 2010; Zhou
et al., 2009). The use of hypomethylating agents and histone de-
acetylase inhibitors has also enhanced the efficiency of iPSC
generation (Huangfu et al., 2008a, 2008b; Mikkelsen et al., 2008).
iPSC lines provide novel models for the study of human
diseases, and gene-corrected iPSCs may provide novel thera-
peutic reagents (Hanna et al., 2007; Raya et al., 2009; Yama-
naka, 2009). Jaenisch, Townes, and colleagues rescued a
humanized sickle cell anemia mouse model by transplanting
gene-corrected iPSCs that had been induced to undergo hema-
topoietic differentiation (Hanna et al., 2007). More recently,
Cantz et al., generated mice from tetraploid embryo aggrega-
tions of gene-corrected iPSCs, proving that genetic manipula-
tion does not diminish the totipotent potential of iPSCs (Wu
et al., 2011).
Although advancements have been made in the generation
of iPSCs, the mechanism behind reprogramming is not yet
completely understood (Yamanaka, 2009). Epigenetic mecha-
nisms are clearly important; reprogramming is associated with
new DNA methylation patterns that presumably reflect the acti-
vation of endogenous pluripotency genes, and repression of
differentiation genes. Ecker and colleagues defined the methyl-
omes of iPSCs at single-base resolution; although they are
globally similar to ESCs, iPSCs have unique patterns of DNA
methylation (Lister et al., 2011). However, the reprogramming
of fibroblasts deficient for Dnmt3A and Dnmt3B (the DNA
methyltransferases responsible for de novo DNA methylation)
revealed that neither of these genes is required for reprogram-
ming (Pawlak and Jaenisch, 2011). This information, coupled
with the fact that iPSCs have a ‘‘memory’’ of the parental cells
from which they were derived (Kim et al., 2010), suggests that
there may be additional, currently unrecognized factors that
are relevant for iPSC generation.
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Although iPSC lines generally have normal karyotypes (Park
et al., 2008; Takahashi et al., 2007; Wernig et al., 2007; Yu
et al., 2007), more recent analyses of iPSC genomes suggest
that there may be more subtle genetic consequences of reprog-
ramming. Hall and colleagues used whole-genome sequencing
data to detect structural variants (SVs) in three iPSC lines derived
from a single reprogramming experiment. They found a very
small number of new SVs in the iPSC lines, suggesting that
reprogramming does not cause genomic instability (Quinlan
et al., 2011), while in contrast, array-based studies revealed
a large number of copy number variants within iPSC genomes,
which evolved with passaging (Hussein et al., 2011; Laurent
et al., 2011; Martins-Taylor et al., 2011). Since submission of
this paper, a report by Ji et al. confirmed this finding, using
whole-exome sequencing of human iPSC lines (Ji et al., 2011).
Gore et al. performed whole-exome sequencing of 22 human
iPSC lines generated with multiple reprogramming strategies
and a variety of donor cell types. They detected an average of
five nonsynonymous point mutations per exome, which were
enriched in genes found in the COSMIC database of cancer-
associated genes (Forbes et al., 2008; Gore et al., 2011), and
the authors concluded that iPSC genomes often contain muta-
tions that may be related to cancer pathogenesis, raising a
potentially important safety issue.
In this study, we performed three experiments utilizing whole-
genome sequencing to define all of the genetic variations
associated with reprogramming. Our data suggest that most
mutations in iPSCs are random and benign, occurring prior to
reprogramming; these preexisting mutations are ‘‘captured’’ by
the cloning event itself. In one experiment, all tested iPSC clones
were derived from the same pool of rare founding cells that
contained a shared set of mutations. Although these mutations
may simply mark ‘‘elite’’ cells with a reprogramming advantage
(a model that was thought to be unlikely by Yamanaka, 2009),
some could potentially contribute to reprogramming fitness by
cooperating with reprogramming factors. Our data suggest
that preexisting mutations in somatic cells will be captured by
any reprogramming strategy that is used, since cell cloning is
required for iPSC generation. By sequencing large numbers of
iPSC clones, recurring mutations in pathways that affect reprog-
ramming efficiency may be discovered, and these mutations
may reveal novel approaches to improve reprogramming effi-
ciency and safety.
RESULTS
Experimental System
To investigate the genetic events associated with transcription-
factor-mediated reprogramming, we generated murine iPSC
lines using an established polycistronic lentivirus containing
three transcription factors, OCT4, SOX2, and KLF4 (OSK)
(Chang et al., 2009). Although it is now possible to reprogram
somatic cells using nonintegrating vectors, the use of an inte-
grating reprogramming vector was necessary to provide a defin-
itive and unique genetic mark for each iPSC clone, which was
crucial for all subsequent steps of the analysis. We transduced
mouse fibroblasts derived from three different mouse strains.
The three donor mice had very different breeding histories: theembryo used to make mouse embryonic fibroblasts (MEFs) in
experiment 1 was a WT littermate from an intercross between
Ybx1+/ founders (Lu et al., 2005). The donor for the WT tail tip
fibroblasts (TTFs) used in experiment 2 was a WT littermate
from an intercross between Casp9+/ mice (Zheng et al.,
2000). The MEFs used in experiment 3 were derived from a
Gusb/ embryo from an intercross between congenic Gusb+/
mice, a murine disease model for Mucopolysaccharidosis type
VII (MPSVII) that has been maintained as an inbred strain at the
Jackson Laboratory. Details of cell culture, transduction, and
iPSC generation are provided in the Experimental Procedures,
and are listed in Table 1.
All clones were examined for morphology and alkaline phos-
phatase reactivity, as well as expression of the pluripotency
markers SSEA-1, Nanog, and Oct4. All clones had characteris-
tics of embryonic stem cells (ESCs) (Table 1). Since experiment
3 utilized MEFs derived from a disease model known to have
growth and developmental defects (MPSVII is caused by a
frameshift mutation in the Gusb gene that creates a null allele),
we extensively characterized these iPSC lines (Meng et al.,
2010; Sands and Birkenmeier, 1993). Affymetrix Mouse Exon
1.0ST arrays were used to compare expression patterns in
MPSVII iPSC lines and embryo-derived MPSVII ESCs (GEO
Accession GSE36017). Unsupervised hierarchical clustering
analysis showed that the iPSC clones and ESC lines clustered
randomly, suggesting that their global patterns of gene expres-
sion are highly similar (Figure S1A, available online). The methyl-
ation status of the Oct4 and Nanog gene promoters was
analyzed by bisulfite modification of genomic DNA from each
of the four lines, along with ESC andMEF controls. The promoter
region of each gene was amplified after bisulfite treatment with
bisulfite-specific primers, followed by deep digital sequencing
of the amplicons on the Roche/454-FLX platform. Each CpG
dinucleotide was covered by an average of 2,944 reads (range:
107 to 6,129), and the percentage of methylated C residues
was determined at each position. The Oct4 and Nanog pro-
moters were extensively methylated in MEFs, but were relatively
unmethylated in ESCs or iPSCs (Figure S1B). Lastly, NOG mice
were injected with 1 million iPSCs from each of the four iPSC
lines; each line formed cystic teratomas containing all three
germ layers (Figure S1C).
Sequence Analysis of the Genomes of the Parental
Fibroblasts (Founder Mice)
It was essential to sequence the genomes of the ‘‘parental’’
MEFs or TTFs from which the iPSC clones were derived as
the appropriate comparator genome for each experiment. The
founding animals used in experiments 1 and 2 were WT litter-
mates of mice containing targeted mutations made in 129/SvJ
ESCs that were injected into C57Bl/6 blastocysts. After germline
transmission of the mutant allele, the mice were backcrossed to
C57Bl/6 mice. The embryo used in experiment 1 was back-
crossed only twice, while the adult mouse used for experiment
2 was extensively backcrossed to C57Bl/6 mice (obtained from
the Jackson Laboratory). To determine the fraction of 129/SvJ
variants in the founder genomes, we compared all SNVs
detected in these genomes to both the reference B6 genome
and the 129/SvJ genome, which we sequenced previously for
the same purpose (Wartman et al., 2011). Our most recentCell Stem Cell 10, 570–582, May 4, 2012 ª2012 Elsevier Inc. 571
Table 1. Pluripotency and Genomic Characterization of iPSC Clones
Experiment
(Parental
Cells) Clone
Age of
Mouse
Days in Culture
for Transduction
ESC-like
Morphology
Alkaline
Phosphatase
Staining
Positive
Flow Cytometric Staining WGS
Haploid
Coverage
OSK
Coverage
OSK
Integration
Positions
SNV
Validation
PlatformPre Post SSEA-1+ Nanog+ Oct 3/4+
1 (MEF) — e13.5 — — — — — — — 55.178 — — —
1 (MEF-
derived
iPSCs)
4 e13.5 6 29 yes yes yes yes yes 46.689 105.175 6:116062660
11:54261983
17:29179146
exome
sequencing
5 e13.5 6 29 yes yes yes yes yes 55.191 176.645 7:20201630
9:34109963
15:8307932
16:36841079
exome
sequencing
9 e13.5 6 29 yes yes yes yes yes 57.668 104.485 12:56888952
X:82219170
exome
sequencing
2 (TTF) — 65d — — — — — — — 22.727 — — —
2 (TTF-derived
iPSCs)
1 65d 20 16 yes yes yes yes yes 26.56 148.404 X:23294264 exome
sequencing
2 65d 20 16 yes yes yes yes yes 24.377 66.531 7:102410141
9:41255493
exome
sequencing
3 65d 20 16 yes yes yes yes yes 30.255 75.629 3:65184739
7:66559629
10:30896454
12:70688422
14:97803433
exome
sequencing
3 (Gusb/ MEF) — e13.5 — — — — — — — 17.877 — — —
3 (Gusb/
MEF-derived
iPSCs)
1 e13.5 17 24 yes yes yes yes yes 28.896 20.387 5:16530376
9:72205724
Roche/
454-FLX
2 e13.5 17 24 yes yes yes yes yes 23.958 12.279 4:139018701
14:84892429
Roche/
454-FLX
5 e13.5 17 24 yes yes yes yes yes 19.591 12.603 14:6229265 Roche/
454-FLX
6 e13.5 17 24 yes yes yes yes yes 22.005 13.74 12:99479785
16:38231164
Roche/
454-FLX
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Figure 1. OSK Lentivirus Insertion Sites for the Three Reprogram-
ming Experiments
Insertion sites of the OSK lentivirus for each iPSC clone are indicated on
a representation of the 20 mouse chromosomes. Sites of integration were
determined by whole-genome sequencing. Each iPSC line had one to five
lentiviral insertion sites. The first number next to each insertion site refers to the
experiment, and the second refers to the clone. Experiment 1 insertion sites
are indicated in green, experiment 2 in red, and experiment 3 in blue.
Cell Stem Cell
Whole-Genome Sequencing of Murine iPSC Clonesalignment and filtering algorithms revealed that the 129/SvJ
genome contains 4,434,171 SNVs. We first compared each of
the fibroblast genomes to the reference (C57Bl/6) genome. In
the founding MEFs from experiment 1, a total of 497,691 SNVs
were detected (237,319 were heterozygous, and the remainder
homozygous). Of these variants, 476,002 (95.64%) were iden-
tical to 129 SNVs; the high number of 129 variants reveals the
short backcrossing history of these mice. The TTFs from exper-
iment 2 contained a total of 8,002 SNVs (5,702 heterozygous,
and the remainder homozygous), of which 4,125 (51.55%)
were identical to 129 SNVs; this data reveals the extensive back-
crossing of these mice to B6. Finally, the MEFs used in experi-
ment 3 contained a total of 7,278 SNVs (5,192 heterozygous,
and the remaining homozygous), of which 4,317 were identical
to 129 SNVs (59.32%). Despite the long history of intercrossing
of these mice, a very small amount of residual 129 strain
‘‘contamination’’ is still apparently present in their genomes.
The large number of private variants present in each mouse
genome demonstrates the absolute necessity of sequencing
the founder cell genomes as the comparator for derivative
iPSC genomes.
Genomic Architecture of iPSC Clones
Genomic DNA from each iPSC line and their parental fibroblasts
were used to make libraries that were subjected to paired-end
sequencing on the Illumina GAIIX or HiSeq 2000 platform. The
three iPSC genomes from the first experiment were sequenced
to an average haploid coverage depth of 553; we learned that
this was far greater than what was required for mutation dis-
covery from inbred mouse genomes (Wartman et al., 2011).
The average haploid coverage of the genomes for the second
experiment was therefore 233, and for the third experiment,
183 (Table 1). The variants for all genomes were deposited in
the Short Read Archive (SRP011044). We first mapped the
genomic integration sites of the polycistronic OSK lentivirus in
every clone to establish that each clone was genetically unique.
Each iPSC line had 1–5 distinct lentiviral insertion sites, which
established the unique genetic identity of each clone (Table 1
and Figure 1A). For experiment 3, we used expression array
data from each clone to demonstrate that the lentiviral insertions
did not detectably alter expression of surrounding genes (two
megabases upstream and downstream from each insertion
site) in any clone (data not shown).
The genome of each iPSC clone was compared to its own
parental fibroblast genome to define all acquired variants in the
iPSC clone. Compared to its own parental line, each iPSC clone
contained a range of 190–773 SNVs (Figure 2A), with an average
of 11 SNVs (range 3–19) locatedwithin coding regions (Figure 2B,
Table S1). To assess the fidelity of our calling algorithms, we
determined the number of 129 SNVs among the total SNVs de-
tected in each iPS genome; if the algorithms were accurate,
very few of the sequence variants should have been identical
to 129 SNVs, and this was indeed the case. For experiment 1,
only 2/907 (0.22%) SNVs were from the 129 strain; for ex-
periment 2, 8/2083 SNVs (0.38%) were 129 derived; and for ex-
periment 3, 42/2130 SNVs (1.97%) were identical to 129 SNVs.
Plotting the location of each SNV within the genome reveals
that the variants are widely distributed throughout the genome
(Figure S2). All four iPSC lines (and the starting MEF cell pool)derived from theGusb/mice contained the expected homozy-
gous single-base deletion (del C) in the tenth exon of the Gusb
gene that creates the frameshift mutation that inactivates the
gene (Sands and Birkenmeier, 1993).
The digital read counts provided by whole-genome se-
quencing allowed us to calculate the variant allele frequencies
of all SNVs. Variant allele frequency plots revealed that the
variant frequency is distributed around a mean of 50%, with
a normal distribution (Figure 3A and Figure 5). This suggests
that the vast majority of variants are heterozygous, and present
in nearly all cells within the iPSC sample.
Indels and SVs
Wetested for somatically acquiredSVs inall threeexperimentsby
comparing sequencing read depths across the genomes of the
iPSC clones versus parental fibroblasts. We found no high confi-
dence SVs in experiment 1, and twoSVs in experiment 2. In clone
1, a 740 kb, single-copy amplificationwas found on chromosome
11 between positions 87,990,000 and 88,730,000. In clone 2,
a single copyamplification of 850kbpwas foundonchromosome
14 between positions 11,530,000 and 12,380,000. In experi-
ment 3, we found one single copy number amplification thatCell Stem Cell 10, 570–582, May 4, 2012 ª2012 Elsevier Inc. 573
Figure 2. Numbers of SNVs Identified in Each iPSC Clone
(A) Total number of SNVs (including a small fraction of loss of heterozygosity sites) detected in each iPSC clone compared to its parental fibroblasts. Related to
Figure S2.
(B) Total number of SNVs detected in the coding regions of each iPSC clone compared to its parental fibroblasts, listed in Table S1. Pathway analysis of these
SNVs is shown in Table S5.
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Whole-Genome Sequencing of Murine iPSC Cloneswas common to all four iPSC clones, which is described in detail
below.
A large number of small insertions and deletions (indels) were
predicted in all iPSC clones from all three experiments. However,
we did not secondarily validate these variants because the
frequency of false positives is very high with our current calling
algorithms (see Experimental Procedures). However, for experi-
ment 3, we detected a set of 32 identical indels (out of several
hundred predicted in each clone) that were common to all four
iPSC clones (Table S3). Because these indels were identical in
all four clones, we are confident that they are real.
Mutational Consequences of SNVs
The calling algorithms used for SNV detection, and the sensitivity
and specificity of the calling algorithms, are detailed in the
Experimental Procedures section. All of the SNVs reported
within coding regions were secondarily validated by exome
sequencing for experiments 1 and 2, or by Roche/454-FLX
sequencing of specific PCR-amplified regions for experiment 3
(Table S1). Each iPSC clone contained an average of 11 vali-
dated coding region SNVs per genome (including missense,
nonsense, splice site, and silent mutations). None of these
were identical to 129/SvJ SNVs. In addition to the coding muta-
tions, each clone contained hundreds of predicted SNVs in
noncoding regions of the genome (Figure 2A). For the three
iPSC clones in experiments 1 and 2, all of the SNVs were unique
to each iPSC genome, and there was no overlap among the
variants detected in each clone or experiment (Figure 3B).
However, among the 459–698 total SNVs detected in each
iPSC genome in experiment 3, we detected 157 SNVs (5 within
coding regions) that were common to all four iPSC lines (Figures
4A and 4B, Table S2).We tested for the five shared coding region
SNVs in two additional iPSC lines generated from the same
experiment, and both were heterozygous for all five variants
(data not shown). Each of the iPSC clones in this experiment
had unique lentiviral insertion sites, and each had a set of private
mutations that did not overlap among the clones. Each clone
was therefore genetically distinct. We tested for two of the574 Cell Stem Cell 10, 570–582, May 4, 2012 ª2012 Elsevier Inc.shared mutations (Apaf1 G16A and Sbno2 A3783G) in a second
reprogramming experiment using TTFs derived from a different
Gusb/ mouse, and detected neither SNV in any of 10 iPSC
clones tested (data not shown). Using expression array data
from each of the Gusb/ iPSC clones, we found that none
of the shared SNVs altered the expression of any ‘‘nearest
neighbor’’ genes (data not shown).
To further confirm that the four iPSC clones from experiment 3
had a shared set of genetic variants, we also searched for shared
indels and SVs, as noted above. Somatic indel prediction anal-
ysis identified 32 identical indels that were present in all four
iPSC clones (Table S3); none had a translational effect. We
also identified a shared amplified region of 130 kilobases on
chromosome 6 that was present in all four iPSC clones, but
not in the parental MEFs (Figure 4C). Two genes are located
within this region, Mug2 (a protease inhibitor) and Gm10319
(a predicted gene). Gm10319 was not significantly overex-
pressed in the iPSC clones compared to Gusb/ ESCs, and
the mouse Exon1.0 array did not contain probesets for Mug2,
so we could not evaluate its expression (data not shown).
The identification of a large set of shared genetic variants
strongly suggests that all four of these iPSC lines arose from
rare cells within the MEF pool that contained a set of identical
variants. However, none of the shared SNVs were reliably
detected in the parental MEFs even with deep read counts
obtained when the mutations were validated (average 2,3083,
range 7763 to 4,3123 coverage for each SNV, data not shown).
Importantly, rare variant detection on the Roche/454-FLX plat-
form is limited by an error rate of 1% (Gilles et al., 2011), sug-
gesting that the shared variants were present in less than 1% of
the total cells in the MEF pool. In an attempt to detect these rare
cells among the parental MEFs, we decided that we must limit
our analysis to several hundred cells at a time. We devised
a strategy that took advantage of novel StuI restriction sites
created by two of the shared coding region mutations (i.e.,
Apaf1 G16A and Sbno2 A3783G). We amplified regions con-
taining these variants with PCR, and then cloned these ampli-
cons into the pCR2.1 vector (Invitrogen, Carlsbad, CA). Plasmid
Figure 3. SNVs in iPSC Clones from Experiments 1 and 2
(A) Variant allele frequency plots of all SNVs for each of the iPSC clones from experiments 1 and 2. Two plots are shown for each clone: kernel density (top) and
iPSC variant allele frequencies by sequence coverage (bottom). The traditional kernel density estimation (KDE, Experimental Procedures) reveals that each iPSC
sample is composed of a single dominant clone, with no apparent subclones.
(B) Relationship of the total SNVs detected within each iPSC clone. No shared SNVs were detected in any clone in either experiment. Overlapping regions of the
Venn diagram with no numbers contain no SNVs.
Cell Stem Cell
Whole-Genome Sequencing of Murine iPSC ClonesDNA preparations derived from minilibraries containing
hundreds of cloned amplicons were then digested with EcoRI
(to release the entire insert from the plasmid backbone) and
StuI (to detect clones containing the variant alleles), and the
digestion products were resolved using Southern blot analysis.
Figure 4D shows representative blots of the Apaf1 and Sbno2
analyses. DNA from a pool of clones from one of the iPSC lines
reveals that StuI cuts 50% of the starting DNA. However,
most pools of clones derived from the MEFs revealed no diges-tion products. Only occasional pools contain very small amounts
DNA cleaved by StuI, suggesting that no more than a few clones
within the pool contain the variant allele. To estimate the
frequency of the clones containing the variant allele in these
positive pools, the same pools were sequenced on an Illumina
HiSeq 2000, with >50,0003 coverage of the variant position.
The variant allele was detected in 0.153% of the Apaf1 reads
in a pool containing 662 colonies, suggesting that only one clone
contained themutation. In the other experiment, the variant alleleCell Stem Cell 10, 570–582, May 4, 2012 ª2012 Elsevier Inc. 575
Figure 4. Shared Genomic Variants Identified in All Four iPSC Clones from Experiment 3
(A) Relationship of the SNVs detected within the coding regions of each iPSC clone. Private and shared mutations were found in all four clones. Overlapping
regions of the Venn diagram with no numbers contain no SNVs. Pathway analysis of these SNVs is shown in Table S5.
(B) Relationship of the total SNVs (including a small fraction of loss of heterozygosity sites) for each iPSC clone. Overlapping regions of the Venn diagram with no
numbers contain no SNVs. Shared SNVs are listed in Table S2 and shared indels are listed in Table S3.
(C) An identical SV was identified in all four iPSC clones from experiment 3, spanning 130,000 bp on chromosome 6.
(D) Detection of shared variants in rare cells from the parental MEF pool. Regions containing the SNVs within the Apaf1 and Sbno2 genes were amplified from the
Gusb/ MEF starting pool from experiment 3, and these amplicons were directly ligated into the pCR2.1 vector. The ligation products were transformed into
E. coli; ampicillin-resistant colonies were counted on each 10 cmplate, and pooled. Plasmid DNAwas prepared from each pool, and digested with StuI and EcoRI
to detect the novel StuI sites generated by the Apaf1 G16A and Sbno2 A3783G variants. Digestion products were separated on 5% polyacrylamide gels,
transferred to nitrocellulose, and analyzed by Southern blotting. Expected fragment lengths are indicated below the Southern blots. (*) indicates the variant-
specific digestion products. Quantification data from Illumina sequencing validation is shown in Table S4.
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Whole-Genome Sequencing of Murine iPSC Cloneswas detected in 1.016% of the Sbno2 reads in a pool containing
141 colonies, suggesting that one or two clones contained the
mutation (Table S4). The total variant frequency was calculated
to be 0.037% and 0.199% for Apaf1 and Sbno2, respectively,
by taking into account the total number of clones from all nega-
tive pools within the same experiment (indicated in Figure 4D).
This analysis suggests that fewer than 1 cell in 500 from the start-
ing pool contained the shared variants detected in all of the iPSC
clones.576 Cell Stem Cell 10, 570–582, May 4, 2012 ª2012 Elsevier Inc.In addition to the shared variants in the iPSC clones of exper-
iment 3, therewere also 302–540 unique (‘‘private’’) SNVs in each
of the clones (Figure 4B). We compared the variant allele fre-
quencies of the shared SNVs versus the private SNVs. As
expected, the shared variants all had variant allele frequency
distributions with a single peak at about 50%, since these muta-
tions must have occurred prior to reprogramming (Figure 5, left
panels). While the majority of the private SNVs are also present
in 50% of reads, clones 1, 2, and 6 contained a small shoulder
Figure 5. Comparison of Shared Versus Private Variant Allele Frequencies for Experiment 3
Left and Center panels: Variant allele frequencies for the shared and private SNVs from the iPSC clones of experiment 3 were plotted. Two plots are shown for
each clone: kernel density (top) and iPSC variant allele frequencies by sequence coverage (bottom). The shared SNVs have a single dominant clone with a peak
variant allele frequency of 50% (left panels). The private SNVs in each clone also have a major peak of variant allele frequency of 50%, but the suggestion of
a second peak at 25% is suggested in clones 1, 2, and 6. The second peak was confirmed only for clone 1 (red arrowhead). Right panels: Validation of variant
allele frequencies in iPSC clones. Using whole-genome sequencing data, we selected ten variants with predicted variant allele frequencies (VAFs) of 50% versus
25% for each of the iPSC clones, amplified all variants by PCR, and then performed deep sequencing on the Roche/454-FLX platform. VAFs were plotted for each
clone for whole-genome sequencing (x axis, VAF byWGS) versus deep sequencing (y axis, VAF by Roche/454-FLX). For clone 1, the variants with VAFs of25%
were statistically confirmed by deep sequencing (p = 0.000045). For the other three clones, the variants with predicted 25% VAF were not confirmed (p > 0.05 for
all three).
Cell Stem Cell
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Whole-Genome Sequencing of Murine iPSC Clonesin the distribution at 25% variant allele frequency, suggesting
that a subclone may be present within these samples (Figure 5,
middle panels). The presence of a true subclone in clone 1 was
validated by examining the deep read counts of 10 randomly
selected mutations with a variant allele frequency of 25%,
versus 10 with a 50% variant allele frequency (Figure 5, right
panels). In clones 2 and 6, the presence of a subclone was not
confirmed.
Other than the shared variants detected in experiment 3, there
was no overlap in the genes containing SNVs among the three
experiments. We also compared all of the genes with coding
region SNVs in our data set to that of Gore et al., who sequenced
the exomes of 22 human iPSC lines. A single gene, ATM/Atm,
contained an SNV in both data sets: in our study, clone 5 from
experiment 1 contained a splice site mutation at the 50 end of
intron 23, whereas one of the 22 human iPSC clones contained
a nonsynonymous SNV in ATM (L752P) (Gore et al., 2011).
Gore et al. also reported that their human iPSC clones dis-
played a significant enrichment of mutations in genes found in
the COSMIC database (Gore et al., 2011). We therefore exam-
ined the 89 unique genes with coding region SNVs in our 10
iPSC clones, and found that 36 (40.4%) were in the COSMIC
database (Table S1). We also searched the COSMIC database
for the 247 genes with homozygous variants in the three parental
mice used in this study (compared to the B6 reference genome);
36.1% of these genes are likewise in COSMIC, a value that is not
significantly different from that of the iPSC clones (p = 0.5733).
We performed a pathway analysis using the Mutational Signif-
icance in Cancer (MuSiC) suite (N. Dees, Q. Zhang, C. Kandoth,
M.C.W., W. Schierding, D. Koboldt, T. Mooney, M. Callaway, D.
Dooling, E.R.M., R.K.W., and L.D., data not shown) to test for
significantly mutated genes (SMGs), and common pathways
that might be affected by mutations among the 10 clones. The
only SMGs were the four that contained shared missense vari-
ants identified in experiment 3. A total of 50 pathways con-
tained genes that were mutated (Table S5). Only 13 of these
had p < 0.05, and all included one of the shared variants from
experiment 3. There were no pathways with mutations common
to all 10 clones.
DISCUSSION
In this study, we defined the genetic landscapes of 10 indepen-
dent murine iPSC clones by whole-genome sequencing. In
the first two experiments, we identified several hundred SNVs
in each individual clone (with an average of 11 in coding
sequences), but found no overlap among the mutations in any
of the clones. In the third experiment, however, we identified
a subset of shared variants in all four iPSC clones, as well as
a set of ‘‘private’’ variants in each. Using genomic DNA from
the parental MEFs used to create these clones, we were able
to detect two of the shared mutations at a very low frequency,
demonstrating that rare cells within the total MEF population
contained these mutations. Our data suggest that many SNVs
may occur at or before the time of reprogramming, but some
may occur during expansion of the iPSC clones in culture.
Regardless, all of the iPSC lines tested contained hundreds of
mutations. Although most are probably functionally irrelevant,
some could potentially contribute to reprogramming fitness.578 Cell Stem Cell 10, 570–582, May 4, 2012 ª2012 Elsevier Inc.The use of whole-genome sequencing, with assessment of the
variant allele frequencies of hundreds of mutations, is a very
powerful tool that has allowed us to begin to assess whether
themutations detected in iPSC clones are caused by reprogram-
ming, or whether they simply represent the genetic ‘‘history’’ of
the cell that was reprogrammed. In the first two experiments,
this issue could not be resolved. All SNVs in all six clones were
unique, with variant allele frequencies of 50%, suggesting
that most of the SNVs were heterozygous and present in nearly
all of the iPSCs in the clone. Three scenarios could explain these
results: (1) the SNVs preexisted in the cell that was reprog-
rammed, and reflect ‘‘fixation’’ of the background mutations
that were present in that cell by cloning; (2) the variants concur-
rently arose in a ‘‘burst’’ of mutational activity when the lentivirus
integrated, but they were not relevant for outgrowth of the clone;
or (3) the SNVs all arose in a burst of mutational activity after
reprogramming; one or more mutations was important for selec-
tion, and the entire group of mutations in that cell was genetically
fixed by cloning. Based on the background rate of mutations in
somatic cells (Warren et al., 1981), and the large numbers of
mutations detected in each clone, we suspect that the latter
two scenarios are unlikely, although they cannot be definitively
ruled out with the data from the first two experiments.
In the third experiment, however, we detected a large set of
shared mutations in all four iPSC clones that were sequenced,
including SNVs, indels, and an SV; we detected 5/5 coding
SNVs tested in two other iPSC clones generated in the same
experiment. Importantly, these shared variants were not de-
tected in 10 iPSC clones derived from another reprogramming
experiment using fibroblasts from an independent Gusb defi-
cient mouse, i.e., the shared mutations were not related to the
mouse strain itself. Using techniques that could detect point
mutations in rare cells, we were able to detect two of the shared
mutations at a very low frequency (<1 in 500 cells) in the starting
MEF pool; it is clear that this small subset of MEFs was more
likely to undergo reprogramming than the ‘‘average’’ MEF cell
in the pool. Although theMEFs used in experiment 3 had a slightly
higher overall reprogramming efficiency than those from experi-
ment 1 (1/7,500 cells versus 1/14,000 cells; see Experimental
Procedures for details), many more clones would have to be
sequenced to define the actual reprogramming advantage of
the cells with the shared mutations. However, a relatively small
improvement in efficiency (e.g., 5- to 10-fold) could probably
have yielded the observed results, since we only sampled six
clones. Although we do not know whether any of the shared
mutations contributed to reprogramming fitness, sequencing
the genomes of large numbers of iPSC clones from independent
pools of starting cells may allow the identification of recurrently
mutated genes (or pathways) in iPSC clones. These data could
potentially help to elucidate the genetic barriers to reprogram-
ming, and provide novel approaches for improving the efficiency
of the process.
Shared mutations in ‘‘sister’’ iPSC clones from the same re-
programming experiment have also recently been reported by
Gore et al. These authors performed whole-exome sequencing
of 22 human iPSC lines that were created with a variety of
reprogramming approaches (including four-factor retroviral and
lentiviral vectors, three-factor retroviral vectors, episomal plas-
mids, and messenger RNA). Among this set, seven pairs of
A B
Figure 6. Model for the Acquisition of Genetic Variants during iPSC Reprogramming
(A) Model for the genetic variants detected in experiments 1 and 2. Each cell has a unique set of preexisting background mutations, which are ‘‘captured’’ by the
expansion and cloning of single cells with reprogramming. Not all cells transducedwith the reprogramming vector yield iPSC clones, as suggested by the X’s. It is
possible that the background mutations in some cells could contribute to reprogramming fitness.
(B) Model for the data obtained for experiment 3. Preexisting background mutations in rare cells mark their fitness for reprogramming. Private mutations must be
acquired after the shared mutations, and could have arisen at different times: (1) between the time when the shared mutations were acquired and when
reprogramming occurred; (2) at the time of reprogramming; or (3) after reprogramming. Some mutations arising after reprogramming may provide a selective
advantage for the outgrowth of subclones.
Cell Stem Cell
Whole-Genome Sequencing of Murine iPSC ClonesiPSC lines were generated from the same parental cells. In
three of the seven pairs, the authors detected shared SNVs
(1–3 shared mutations were detected, along with a few private
mutations in each of the members of the pair). None of these
mutations was detected in other human iPSC clones, and none
were detected in our set of shared mutations. Even though
exome sequencing of iPSC clone pairs can detect only a small
subset of the mutations found by whole-genome sequencing, it
is striking that three out of seven sets of iPSC clones derived
from the same parental cells had shared variants. When com-
bined with our data, 4 of 10 sets of iPSC clones tested had
shared variants. Clearly this is not a rare event. Although the
significance of the shared mutations is unknown, they do not
appear to provide an overall selective advantage for cells
before they are reprogrammed (since they are rare in the starting
population). Although one or more of the shared mutations may
cooperate with reprogramming factors to provide a selective
advantage for the reprogramming, it is formally possible that
none of the shared mutations are relevant for reprogramming
fitness: they simply may be markers for rare cells that are fit for
another reason (e.g., they may have stem-like properties; Yama-
naka, 2009). Many additional studies will be required to discern
among these possibilities.
As noted above, we evaluated variant allele frequencies in the
iPSC clones to help understand the timing of mutational events.The variant allele frequencies of most clones averaged 50%
(Figure 3A and Figure 5), suggesting that most variants are
heterozygous, and present in nearly all of the cells in the sample.
In experiment 3, we further examined the variant allele frequen-
cies of the shared versus private mutations in each clone (Fig-
ure 5). The shared variants had to be present prior to reprogram-
ming, and had an average variant allele frequency of 50%, as
expected. The private variants also had a major peak of variant
allele frequencies at 50%, but one clone was confirmed to
contain aminor, secondary peak at25% that represents a sub-
clone. Clearly, this subclone must have arisen after reprogram-
ming, since it is not present in all cells in the sample. Because
we sampled clones at a single time in their existence, we do
not know whether this late subclone was stable, rising, or falling
in relation to the founding clone. Serial sampling would be
required to resolve this question. However, these results do
suggest that iPSC clones may evolve with serial passaging, as
previously reported (Laurent et al., 2011).
Based on this information, we propose a model of how muta-
tions are acquired during iPSC development (Figure 6). Most of
the time, individual iPSC clones arise from random, unique cells
within the transduced parental cell population. Each cell has
a unique set of preexisting background mutations that are fixed
by the cloning of single cells (Figure 6A), so it is formally
possible that rare cells contain background mutations thatCell Stem Cell 10, 570–582, May 4, 2012 ª2012 Elsevier Inc. 579
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to explain why reprogramming is inherently inefficient), but we
did not find evidence for a common pathway targeted by these
mutations. However, there are some instances where preexist-
ing mutations are associated with a cell’s reprogramming
fitness. These cells are more likely to be reprogrammed and
detected as iPSC clones (Figure 6B). Between the time when
the shared mutations and the reprogramming event occurs,
additional private mutations are acquired (which may or may
not further increase reprogramming efficiency). Finally, addi-
tional mutations can be acquired after reprogramming that
can provide a selective advantage for the outgrowth of
subclones.
These data provide several important caveats for the field of
somatic cell reprogramming. By cloning individual somatic cells,
background genetic variants will invariably be fixed by the act of
cloning, regardless of the strategy used to induce reprogram-
ming. If fitness mutations are present in rare somatic cells, they
could potentially cooperate with reprogramming factors, regard-
less of how the factors are delivered (stably integrated viruses,
transiently expressed plasmids, mRNAs, or proteins). Although
this may have important consequences for the use of iPSC
clones in therapeutic settings, the sequencing of large numbers
of iPSC clones may also provide new strategies for identifying
genes that represent barriers for reprogramming, and suggest
approaches to safely overcome them. Perhapsmost importantly,
these results strongly suggest that somatic cell reprogramming
may not be amutagenic event per se, and that knowledge gained
from sequencing iPSC genomes may help to refine the process
and make it safer for therapeutic purposes.EXPERIMENTAL PROCEDURES
Production of iPSC Clones
We generated iPSC clones from fibroblasts obtained from three different
mouse strains, fully described in the Results section. iPSC clones were gener-
ated from each line as previously described (Chang et al., 2009). Briefly,
33105 fibroblasts were seeded on 6-well plates and allowed to grow over-
night. The next day, the cells were transduced with the OSK lentivirus at an
MOI of 3–5:1. The cells were incubated with virus for 48 hr, trypsinized, and
transferred to a 100 mm dish without a feeder MEF layer. Cells were grown
for 2–3 weeks with daily media changes. After 17 days (Experiments 1 and
3) or 26 days (Experiment 2), individual colonies were picked and expanded
on MEF feeder layers. For experiment 1, 48 iPSC colonies were identified
from 675,000 transduced MEFs (1 in 14,000 cells). For experiment 2, 12 colo-
nies were identified from 675,000 transduced TTFs (1 cell in 57,000). For
experiment 3, 120 colonies were identified from 900,000 transduced MEFs
(1 cell in 7,500).
Pluripotency Characterization of iPSC Clones
All 10 iPSC clones were assessed for ESC-like morphology and stained
for alkaline phosphatase according to the manufacturer’s instructions
(Millipore, Billerica, MA). Cells were analyzed by flow cytometry for the pluripo-
tency markers SSEA-1, Nanog, and Oct4. For intracellular Nanog and Oct4
detection, cells were fixed with 4% paraformaldehyde, and permeabilized
with 1% saponin prior to incubation with antibodies.
lllumina Whole-Genome Shotgun Library Construction
Libraries were prepared for whole genome sequencing essentially as de-
scribedWartman et al., 2011. For exome sequencing, the sequencing libraries
were hybridized with the SureSelectXT Mouse All Exon Kit (Agilent), which
captures 49.6 Mb of the coding sequence from 24,000 genes. KAPA qPCR580 Cell Stem Cell 10, 570–582, May 4, 2012 ª2012 Elsevier Inc.was used to determine the quantity of library necessary to produce cluster
counts appropriate for the Illumina HiSeq 2000.
Illumina Sequencing
After diluting the libraries to a 10 pM concentration, we utilized the paired-end
flow cell and cluster generation kits to produce flow cells with an average
cluster density ranging between 1.9 and 3 million clusters per tile. We
employed the standard sequencing kits (Illumina HiSeq Sequencing Kit) and
performed 2 3 100 cycles of nucleotide incorporation using a paired-end
read approach. We used the Illumina sequencing pipeline, version 1.7 or 1.8,
to analyze the data and produce files containing high quality (‘‘passed filter’’)
reads with associated quality values.
Clonality Analysis
Clonality estimates were determined using the mutation allele frequencies
from whole-genome sequencing. To minimize the effect of coverage outliers
from likely false positives, we prefiltered each site to ensure that the
coverage fell within ±2 median absolute deviations from the median coverage
of all nonrepetitive predictions within each clone. We drew a kernel density
estimate (KDE) plot for variant allele frequencies using the density function
in ‘‘R.’’ A custom R function evaluated each KDE plot to determine the
number of significant peaks, which served as an estimation of the number
and relative composition of different subclones present within each iPSC
clone.
To confirm the presence of subclones and better estimate their frequency,
we randomly selected 10 sites from each major subclone (between 45%–
55% variant allele frequency) and each minor subclone (between 25%–35%
variant allele frequency). These sites were amplified by PCR from the original
sample, and then sequenced on the Roche/454-FLX platform to a median
depth of 6,322 reads. A Student’s t test was used to assess the significance
of the difference in frequencies between the major and minor clones.
Significantly Mutated Gene Analysis and Pathway Analysis
Since the mutational process in clones is analogous to the mutational
process of a tumor, we used components of the MuSiC package (N. Dees,
Q. Zhang, C. Kandoth, M.C.W., W. Schierding, D. Koboldt, T. Mooney,
M. Callaway, D. Dooling, E.R.M., R.K.W., and L.D., data not shown) to deter-
mine SMGs and pathways. The SMG component of MuSiC assigns muta-
tions to various categories, such as transition or transversion, and then
uses methods including convolution, Fisher’s test, and a likelihood test to
combine the category-specific binomials to obtain an overall p value. The
result is appreciably more accurate than if these attributes were disregarded.
The pathway analysis component of MuSiC is an implementation of
PathScan (Wendl et al., 2011).
Sequence Analysis
Reads were aligned using BWA 0.5.5 (Li and Durbin, 2009) with quality
trimming set at 5 to the NCBI build 37 of Mus musculus reference sequence
augmented with an additional contig representing the complete OSK
sequence. The resulting alignments were deduplicated using Picard (http://
picard.sourceforge.net) and quality recalibrated using the GATK (DePristo
et al., 2011) base quality recalibrator (v1.0.3471). All 13 genomes, along with
a 129/SvJ reference genome, were submitted to the SRA database under
accession number SRP011044.
We called potential somatic SNVs using a modified version of
SomaticSniper (Larson et al., 2011) to account for perfectly pure samples. Vari-
ants with a somatic score greater than 10 were filtered on a number of
sequence features to remove false positives as described elsewhere (Koboldt
et al., 2012). Sites passing these filters were additionally filtered to remove vari-
ants where the difference between the clone and control variant allele
frequency was 30% or less and the read depth was 10 reads or less.
The software and parameters used for identifying somatic variants were as
follows. Recalibration: GATK v1.0.3471(—max_reads_at_locus 20000) with
covariates for ReadGroup, QualityScore, Cycle, and Dinucleotide context;
deduplication: Picard1.25 (experiments 2 and 3) or Picard1.36 (experiment 1);
SNV calling: bam-somaticsniper (unreleased version; v1.0.0 should be similar)
-P -f -q 1 -Q 10 –s 0.000001; indel calling: GATK (v1.0.5336) IndelGenoty-
perV2—somatic -window_size 300; SV calling: BreakDancer (v1.1_20100719)
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SquareDancer -q 25 -r 2 -k 25 -n 1 -c 1 -m 3 -e 0.5; CNV calling: CNVHMM
was described in Wartman et al. (2011) (software has not been released); and
readcount: bam-readcount 0.3 -b –q. This softwarehasalsonot been released.
For SNV filtering, read count data was generated as described above, and
filtered identically to the parameters in Koboldt et al. (2012). Those are as
follows:
Max average mapping quality difference (variant-reference) of 30
Max difference (variant-reference reads) of the mean mismatch quality
sum of 50
Max difference (variant-reference) of average clipped read length of 25
Minimum flanking homopolymer length of 5
Minimum average absolute distance to the end of the read [1  (absolute
value of the distance to the center of the clipped read/center of the clipped
read)] of 0.1
Minimum fraction plus strand of variant reads [(number of plus strand
reads)/(total reads)] of 0.01
Maximum fraction plus strand of variant reads of 0.99
Minimum number of variant reads of 4
Minimum average distance of variant to the effective 30 end of 0.2
Minimum variant base frequency of 0.05
Nongenic variants in repetitive regions (as identified from the UCSCGenome
Browser’s RepeatMasker track for mouse build 37) were also excluded from
further analysis (Karolchik et al., 2011); 43.5% of the genome was excluded
from our variant analysis.
Variants passing all filters were annotated as previously described (Wartman
et al., 2011).
For experiment 3, sites chosen for validation were manually reviewed and
validated using Roche/454-FLX sequencing as previously described (Ding
et al., 2010). Read counts were calculated by excluding reads where the called
base was below a phred quality of 15 for WGS data, with a mapping quality of
10 or a base quality of less than 20 for the high depth Illumina data and less
than 20 for the Roche/454-FLX data.
Based on the Roche/454-FLX validation experiment, we uncovered, for 84
sites in experiment 3, via applying a cutoff of >20% variant allele frequency
in the clone and <10% in the MEF sample, that the estimated true positive
rate (specificity) is 78.6% for calls filtered for greater than 103 depth and
variant allele frequency difference of greater than 30%. Applying these filters
resulted in an estimated sensitivity of 85% based on the same Roche/
454-FLX validation data of unfiltered sites. We have previously described the
false negative rate (sensitivity) in Larson et al. (2011), and our simulations
suggest a sensitivity of >99.9% for variants with 50% variant allele frequency
when we have 303 haploid coverage.
Indels were called using the GATK (DePristo et al., 2011). OSK insertion sites
were predicted using BreakDancer (Chen et al., 2009) and SquareDancer, an
in-house implementation of the CREST algorithm (Wang et al., 2011). Copy
number predictions were generated as previously described (Wartman et al.,
2011) and manually reviewed to determine their accuracy.
Detection of Shared Variants in Parental Gusb–/– MEFs
Rare variants detected in the parental MEFs by novel StuI sites were generated
by the Apaf1 G16A and Sbno2 A3783G variants. Regions surrounding each
variant were amplified (Apaf1: 884 bp amplicon, 50-CCCAAACACTTTGATG
AACGA-30 and 50- CTATAAGGACCTTGCTGCGC-30;Sbno2: 806 bp amplicon,
50-GCTGCAGACTGACACAGGAG-30 and 50-AGCAGAGGCTCCCATGACTA-30).
PCR products were cloned into the pCR2.1 vector according to the manufac-
turer’s instructions (Invitrogen, Carlsbad, CA). The number of clones in indi-
vidual transformations was counted on each plate, and then all colonies
were pooled into a single sample (see Table S3 for pool sizes), creating
minilibraries of amplicons from the parental MEF cell DNA. These minilibraries
were then digested with EcoRI to cut the amplicon from the pCR2.1 vector,
and StuI to detect the presence of the variant allele (Apaf1: 391 and 493 bp
products; Sbno2: 454 and 352 bp products). Digestion products were ele-
ctrophoresed on 5% acrylamide gels and transferred to nitrocellulose. Nitro-
cellulose blots were hybridized with 32P-labeled probes (Apaf1: the 493 bp
product; Sbno2: the 352 bp product), washed stringently, and subjected to
autoradiography.ACCESSION NUMBERS
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